Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Charles Peter Kirol, Peloton Interactive's Chief Operating Officer, sold 3,399 shares valued at approximately $19,895 on January 21, 2026. The sale, executed under a pre-established trading plan, coincides with an 8.37% drop in Peloton's stock price over the past week. Despite this decline, some analysts view the stock as potentially undervalued wi…
Aldabra 4 Liquidity Opportunity Vehicle, Inc., a special purpose acquisition company (SPAC), completed its initial public offering (IPO) of over 30 million units priced at $10 each, raising gross proceeds exceeding $300 million. The units began trading on NASDAQ under the ticker 'ALOVU' and include Class A shares and redeemable warrants exercisable…
ExxonMobil's subsidiary, XTO Energy, has initiated a confidential marketing process to sell select assets within the Eagle Ford shale basin in South Texas. Representing approximately 168,000 net acres and valued over $1 billion, these assets include over a thousand wells with a mix of operated, non-operated interests, and royalty positions. This mo…
Gan Hong, Chief Science Officer at SES AI Corporation, completed the sale of 250,000 Class A Common Stock shares totaling approximately $624,705 through market transactions that took place in late January 2026. The sales coincided with the exercise of stock options for the same number of shares at a nominal price. SES AI recently reported substanti…
Kristen Robinson, director at Planet Labs PBC, executed a share sale worth nearly $1.3 million on January 21, 2026, amid soaring stock prices and a recent major government contract. Despite impressive recent returns and strategic growth initiatives, the company faces valuation scrutiny and continued unprofitability.
Gadde Vijaya, a director at Planet Labs PBC, executed the sale of 20,000 Class A Common Stock shares on January 22, 2026, totaling approximately $535,350. The sale comes as the company reached significant stock price milestones and secured a notable multi-year satellite services contract with the Swedish Armed Forces. These events have prompted upw…
Eric Siemers, Chief Medical Officer of Acumen Pharmaceuticals, carried out sales of 3,226 shares of the company’s stock in late January 2026 to satisfy tax liabilities on vested restricted stock units. These transactions occurred under a Rule 10b5-1 plan and do not indicate new insider sentiment. Concurrently, Acumen continues to advance its Alzhei…
Daniel Joseph O’Connell, CEO of Acumen Pharmaceuticals, completed the sale of over 12,000 shares to satisfy tax liabilities tied to restricted stock units, under a pre-established trading plan. The company, focused on Alzheimer’s treatments, recently reported a net loss but continues progress in its clinical trials and collaboration with JCR Pharma…
Matt Zuga, Chief Financial Officer of Acumen Pharmaceuticals, completed stock sales totaling 4,160 shares valued at approximately $7,600 in late January 2026. These transactions were made to satisfy tax withholding obligations linked to vested restricted stock units, following a Rule 10b5-1 plan. Acumen remains focused on progressing Alzheimer’s tr…
On January 22, 2026, Lindblad Sven-Olof, a director and substantial shareholder of Lindblad Expeditions Holdings, Inc., sold 62,100 shares of the company's common stock, executing the transaction near the 52-week high price. The sale was conducted under a Rule 10b5-1 trading plan, generating proceeds exceeding $1 million. Amidst revenue growth and …
Derek M Meisner, Chief Legal Officer and Corporate Secretary of Acumen Pharmaceuticals, Inc., has conducted stock sales totaling $16,720 over three days in January 2026 under a pre-planned trading arrangement. These transactions come as the company continues to focus on its Alzheimer's treatment pipeline, including progressing clinical trials and c…
Aaron Tachibana, serving as CFO and COO of Personalis, Inc., engaged in significant insider transactions involving the purchase and sale of company shares on January 22, 2026. Concurrently, Personalis moves forward with Medicare reimbursement coverage for its advanced cancer monitoring tests and contemplates a sizable stock offering as it prepares …
Shannon L. Devers, Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals, completed a sale of nearly $323,500 worth of stock in late January 2026. The transaction occurred near the company’s 52-week high and precedes an anticipated earnings announcement. Meanwhile, Ionis continues progressing with recent regulatory app…
Following the United States’ formal withdrawal from the World Health Organization (WHO), California has become the first U.S. state to join the WHO’s Global Outbreak Alert and Response Network (GOARN). This move represents California’s commitment to global health collaboration and pandemic preparedness despite federal disengagement from the agency.
Chris Wren, Vice President of Operations at Planet 13 Holdings Inc, liquidated 30,000 company shares in late January 2026, amid the company's efforts to pivot its strategy following less-than-expected third-quarter earnings. Planet 13 reported $23.3 million in revenue and a negative EPS, prompting strategic exits including the California market to …
Amprius Technologies’ Chief Technology Officer, Stefan Constantin Ionel, recently sold over half a million shares totaling around $6.83 million while simultaneously exercising stock options. This activity unfolds during a period of significant stock appreciation and notable company initiatives including a new CEO transition and expanded production …
Michael F. MacLean, CFO of Avidity Biosciences Inc, executed a sale of 4,542 shares worth roughly $329,067 on January 21, 2026, in conformity with company equity incentive policies. The stock transaction occurred near its 52-week peak at $72.74 following a significant annual stock performance gain. In parallel, Avidity unveiled a Managed Access Pro…
Steven George Hughes, Chief Medical Officer at Avidity Biosciences, sold nearly 4,900 shares worth $354,642 to satisfy tax obligations related to recently vested Restricted Stock Units. This sale precedes multiple strategic developments at Avidity, including a new FDA-backed access program for its investigational muscular dystrophy therapy and an i…
W. Michael Flanagan, Chief Scientific Officer at Avidity Biosciences, recently sold 6,534 shares valued at approximately $473,388 to fulfill tax requirements related to restricted stock units. Meanwhile, Avidity is rolling out a Managed Access Program for its drug targeting Duchenne muscular dystrophy and has agreed to be acquired by Novartis in a …
On January 21, 2026, Avidity Biosciences’ President and CEO, Sarah Boyce, executed a sale of 14,387 shares in the company valued at approximately $1.04 million. The transaction, conducted near the stock's 52-week high, was performed to fulfill tax withholding on recently vested restricted stock units, as stipulated by the company's equity incentive…
The New York Federal Reserve carried out rate checks on the dollar/yen pair around midday on Friday, prompting a swift drop in the dollar against the yen. The checks - conducted by the NY Fed acting as fiscal agent for the U.S. Treasury - coincided with market caution about potential intervention as the yen neared 160 per dollar. The Bank of Japan …
On January 22, 2026, Comerica Executive Vice President James McGregor Carr completed a sale of 10,000 shares of company stock valued at roughly $980,600. This transaction occurred at prices close to the stock's annual peak and comes as Comerica pursues a merger with Fifth Third Bancorp, with recent earnings surpassing expectations.
William Radford Lovett II, a notable 10% shareholder of Dream Finders Homes, conducted a sizeable divestiture of Class A shares across two days in January 2026. These transactions unfolded while the company’s stock trades at a low price-to-earnings ratio, accompanied by a recent executive update on an expanded share repurchase plan and fresh market…
James Harry Weber, Executive Vice President of Comerica, executed significant stock sales and option exercises on January 22, 2026, coinciding with Comerica's robust stock performance and a pending merger. Despite Comerica's stock trading above its fair value and a high price-to-earnings ratio, the bank continues to demonstrate financial stability …
Rapid7's Chief Accounting Officer, Scott M. Murphy, has sold a portion of his holdings amid a significant year-over-year share price decline. The move comes ahead of an upcoming earnings report and follows mixed analyst opinions regarding the cybersecurity firm's growth prospects and valuation. Strategic initiatives including partnerships and produ…
